Cannvalate
Cannvalate is a private Australian medical cannabis company founded in 2018 and headquartered in Melbourne, operating in nutraceuticals and drug discovery. Led by CEO Sud Agarwal and co-founders Asaf Katz and Darryl Davies, it employs 11–50 staff.
- Company typePrivate
- Founded2018
- HeadquartersMelbourne, Australia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Cannvalate does
Cannvalate is an Australian medical cannabis company founded in 2018 and headquartered in Melbourne. Per the firm's own positioning, it operates across two stated pillars: nutraceuticals and drug discovery within the medical cannabis sector, with a headcount band of 11–50 employees.
The company's public digital footprint is unusually thin for a firm of its stated scale. Its corporate website at cannvalate.com.au currently displays only a placeholder page indicating the site is under redevelopment, and the listed business-enquiry email is routed to [email protected], a third-party media address rather than a direct corporate channel. The firmographic, product, technology, customer, pricing, partnership, awards, and operating-geographies records in the available data are empty or unpopulated, and no products, services, certifications, or distribution channels are publicly disclosed. The website footer itself describes cannvalate.com.au as a domain-registrant service providing advertising links, suggesting the corporate web presence is in a parked or transitional state.
Leadership is the most concrete element of the public record: CEO Sud Agarwal leads the company alongside co-founders Asaf Katz (Chief Commercial Officer) and Darryl Davies (Chief Operating Officer). The only documented capital event is a $4,000,000 funding round (labeled Round 2) closed on 2018-11-07, with investors and lead investor unspecified. No subsequent capital raises, product launches, partnerships, regulatory milestones, or operational metrics have been disclosed, which materially limits independent verification of the company's current commercial activity.
Cannvalate firmographics
Firmographics- Name
- Cannvalate
- Website
- https://cannvalate.com.au
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cannvalate is a private Australian medical cannabis company founded in 2018 and headquartered in Melbourne, operating in nutraceuticals and drug discovery. Led by CEO Sud Agarwal and co-founders Asaf Katz and Darryl Davies, it employs 11–50 staff.
- Ownership category
- akta.pro rank
Cannvalate industry classification
Industry- Product category
- Medical Cannabis Pharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)
- akta.pro secondary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where Cannvalate is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Markets served
Cannvalate business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Cannvalate product offering
Product offeringCore offering
Cannvalate is a medical cannabis firm that develops and provides nutraceuticals and drug discovery services. Founded in 2018 and headquartered in Melbourne, Australia, the company operates in the medical cannabis industry with a small team of 11-50 employees focused on cannabis-based nutraceutical products and pharmaceutical research.
Differentiator
Problem solved
Functional benefit
Products and services
- Nutraceuticals
Companies that use Cannvalate
Customer profileIdeal customer profiles1 record
Cannvalate technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cannvalate partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights1 record
Cannvalate competitors and assessment
Company assessmentDirect peers
- Cann Group Limited: Australian licensed medicinal cannabis cultivator and manufacturer that supplies extracted and formulated cannabinoid products to patients and partners — directly comparable geography, regulatory regime, and clinical-product focus to Cannvalate.
- Little Green Pharma: Australian-listed medicinal cannabis producer and distributor of formulated cannabis oils and flower products — similar Australian footprint and clinical-product mix to Cannvalate.
- Elixinol Wellness: Australian-listed company selling hemp-derived nutraceutical and cannabinoid wellness products globally — directly overlaps with Cannvalate's nutraceutical activity in the cannabis-adjacent consumer health category.
- Zelira Therapeutics: Clinical-stage cannabinoid therapeutics company running drug-discovery and formulation programs targeting specific indications — directly comparable to Cannvalate's drug-discovery and nutraceutical positioning.
- Althea Group Holdings: Australia-based medical cannabis company selling formulated cannabinoid products through a pharmacy and prescriber network — closely mirrors Cannvalate's clinical-cannabis + patient-services model.
- AusCann Group Holdings: Australian medical cannabis company developing and supplying cannabinoid-based pharmaceutical products to prescribers — comparable in clinical/pharmaceutical positioning and Australian regulatory environment to Cannvalate.
- Medlab Clinical: Australian pharmaceutical company developing cannabis-based and other prescription therapeutics for specific indications — comparable drug-discovery and clinical-pharma focus in the same regulatory environment.
- MGC Pharmaceuticals: Australia/UK-based cannabis pharmaceutical company developing phytocannabinoid-derived prescription medicines and nutraceuticals — comparable clinical/pharmaceutical and nutraceutical dual model.
Broad incumbents
- Ecofibre: Australian hemp and cannabis company with nutraceutical (Ananda Health) and medicinal cannabis divisions — comparable breadth across nutraceuticals and cannabis therapeutics.
- MMJ Group Holdings: Australia-based investment company with exposure across medicinal cannabis cultivation, products, and pharma R&D — a broader portfolio player in the same clinical-cannabis space Cannvalate operates in.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Cannvalate financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cannvalate leadership team
Management profileNumber of profiles
Profiles3 records
Cannvalate funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cannvalate M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cannvalate
What does Cannvalate do?
Cannvalate is a medical cannabis firm that develops and provides nutraceuticals and drug discovery services. Founded in 2018 and headquartered in Melbourne, Australia, the company operates in the medical cannabis industry with a small team of 11-50 employees focused on cannabis-based nutraceutical products and pharmaceutical research.
When was Cannvalate founded?
Cannvalate was founded in 2018. It employs 11 to 50 people.
Where is Cannvalate based?
Cannvalate is headquartered in Melbourne, Australia, in the Oceania region.
Who are Cannvalate's main competitors?
Direct peers on record are Cann Group Limited, Little Green Pharma, Elixinol Wellness, Zelira Therapeutics, Althea Group Holdings, AusCann Group Holdings, Medlab Clinical and MGC Pharmaceuticals. Broad incumbents are Ecofibre and MMJ Group Holdings.
Does Cannvalate have an API?
No public API is recorded for Cannvalate.
What industry is Cannvalate in?
Cannvalate's product category is Medical Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services), with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325411 and its SIC code is 2834.